Abstract
Between 1982 and 1996, 20 patients (10 male, 10 female) with severe aplastic anemia (SAA) with a median age of 25 years (17–37 years), received grafts from an HLA-identical sibling (n = 17), HLA-identical unrelated donor (n= 2) or identical twin (n= 1). The median time from diagnosis to marrow transplantation (BMT) was 15 months (range 1–96 months). More than half of the patients had received more than 10 units of red blood cells or platelet transfusions prior to BMT. Pretransplant immunosuppression consisted of cyclophosphamide (CY) alone (n= 10), CY in combination with total body irradiation (n= 8), and CY and antithymocyte globulin (n= 2). For graft-versus-host disease (GVHD) prophylaxis methotrexate (MTX) alone (n= 9) or MTX with cyclosporin A (n = 10) were given. One patient died on day 18 after marrow grafting due to infection; all other patients had complete and sustained engraftment (95%). Eight patients developed acute GVHD (42%), nine patients chronic GVHD (53%) including four with extensive disease manifestation. One patient experienced a secondary malignancy 11 years after BMT. Eighteen patients followed for a median of 9.45 years (0.42–14.7 years) have sustained hematological reconstitution and are alive and well with a Karnofsky performance score of at least 90%. Thus, excellent long-term survival and low morbidity make allogeneic or syngeneic BMT the treatment of choice for younger patients with severe aplastic anemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reiter, E., Keil, F., Brugger, S. et al. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia. Bone Marrow Transplant 19, 1191–1196 (1997). https://doi.org/10.1038/sj.bmt.1700819
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700819
Keywords
This article is cited by
-
Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults—a single-centre experience
Annals of Hematology (2008)
-
CsA-based post-graft immunosuppression: the main factor for improving outcome of allografted patients with acquired aplastic anemia. A retrospective survey by the Spanish Group of Hematopoietic Transplantation
Bone Marrow Transplantation (2002)